HRP20070452T3 - Sulfonamidni derivati namijenjeni liječenju bolesti - Google Patents

Sulfonamidni derivati namijenjeni liječenju bolesti

Info

Publication number
HRP20070452T3
HRP20070452T3 HR20070452T HRP20070452T HRP20070452T3 HR P20070452 T3 HRP20070452 T3 HR P20070452T3 HR 20070452 T HR20070452 T HR 20070452T HR P20070452 T HRP20070452 T HR P20070452T HR P20070452 T3 HRP20070452 T3 HR P20070452T3
Authority
HR
Croatia
Prior art keywords
alkyl
group
disease
treatment
cycloalkyl
Prior art date
Application number
HR20070452T
Other languages
English (en)
Croatian (hr)
Inventor
D Brown Alan
James Kim
A.L. Lane Charlotte
B. Moses Ian
M. Thomson Nicholas
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20070452(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406388A external-priority patent/GB0406388D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20070452T3 publication Critical patent/HRP20070452T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/42—Y being a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HR20070452T 2004-01-22 2005-01-12 Sulfonamidni derivati namijenjeni liječenju bolesti HRP20070452T3 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04290168 2004-01-22
GB0406388A GB0406388D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60025904P 2004-08-09 2004-08-09
PCT/IB2005/000112 WO2005080324A1 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (1)

Publication Number Publication Date
HRP20070452T3 true HRP20070452T3 (hr) 2008-02-29

Family

ID=43063961

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070452T HRP20070452T3 (hr) 2004-01-22 2005-01-12 Sulfonamidni derivati namijenjeni liječenju bolesti

Country Status (40)

Country Link
US (1) US7351742B2 (de)
EP (1) EP1708992B1 (de)
JP (1) JP4036343B2 (de)
KR (1) KR100785580B1 (de)
CN (1) CN1910144B (de)
AP (1) AP2378A (de)
AR (1) AR047510A1 (de)
AT (1) ATE369333T1 (de)
AU (1) AU2005214154B2 (de)
BR (1) BRPI0507041A (de)
CA (1) CA2553293C (de)
CO (1) CO5720993A2 (de)
CY (1) CY1106894T1 (de)
DE (1) DE602005001929T2 (de)
DK (1) DK1708992T3 (de)
DO (1) DOP2005000004A (de)
EA (1) EA009735B1 (de)
EC (1) ECSP066701A (de)
ES (1) ES2289691T3 (de)
GE (1) GEP20084452B (de)
HN (1) HN2005000030A (de)
HR (1) HRP20070452T3 (de)
IL (1) IL176629A (de)
MA (1) MA28303A1 (de)
ME (1) ME00557A (de)
MY (1) MY139690A (de)
NL (1) NL1028086C2 (de)
NO (1) NO20063761L (de)
NZ (1) NZ548235A (de)
OA (1) OA13361A (de)
PA (1) PA8621901A1 (de)
PE (1) PE20050765A1 (de)
PL (1) PL1708992T3 (de)
PT (1) PT1708992E (de)
RS (1) RS50538B (de)
SI (1) SI1708992T1 (de)
TW (1) TWI273099B (de)
UA (1) UA82283C2 (de)
UY (1) UY28724A1 (de)
WO (1) WO2005080324A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
CN101223132A (zh) * 2005-07-18 2008-07-16 辉瑞有限公司 制备磺酰胺衍生物的方法
JP2009504624A (ja) 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007107828A2 (en) 2006-03-20 2007-09-27 Pfizer Limited Amine derivatives
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
WO2008041095A1 (en) * 2006-10-04 2008-04-10 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
DE102007018151A1 (de) 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US7713463B1 (en) * 2007-11-13 2010-05-11 Nuvasive, Inc. Method of manufacturing embroidered surgical implants
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
US8263623B2 (en) * 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
MX2011007036A (es) 2008-12-30 2011-07-20 Pulmagen Therapeutics Inflammation Ltd Compuestos de sulfonamida para el tratamiento de trastornos respiratorios.
MX2011011156A (es) 2009-04-23 2011-11-04 Theravance Inc COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
CA2760284A1 (en) 2009-05-29 2010-12-02 Pfizer Limited Novel glucocorticoid receptor agonists
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
ME02297B (me) 2011-06-10 2016-02-20 Chiesi Farm Spa Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
BR112015012730B1 (pt) 2012-12-06 2022-07-05 Chiesi Farmaceutici S.P.A. Composto, composição farmaceutica, dispositivo, uso de um composto e combinação
AR093832A1 (es) 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
EP4171525A1 (de) 2020-06-26 2023-05-03 Mylan Pharma UK Limited Formulierungen mit 5-[3-(3-hydroxyphenoxy)azetidin-1-yl!-5-methyl-2,2-diphenylhexanamid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) * 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US7048994B2 (en) * 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
WO2003099764A1 (en) * 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
EP1477167A1 (de) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivative als beta2 agonist

Also Published As

Publication number Publication date
BRPI0507041A (pt) 2007-06-12
WO2005080324A1 (en) 2005-09-01
DOP2005000004A (es) 2005-07-31
NL1028086C2 (nl) 2006-05-09
UA82283C2 (uk) 2008-03-25
JP2007518790A (ja) 2007-07-12
KR20060127073A (ko) 2006-12-11
ME00557A (en) 2011-12-20
DK1708992T3 (da) 2007-11-05
AU2005214154A1 (en) 2005-09-01
US7351742B2 (en) 2008-04-01
US20050171147A1 (en) 2005-08-04
NO20063761L (no) 2006-10-23
HK1096083A1 (en) 2007-05-25
IL176629A0 (en) 2006-10-31
RS50538B (sr) 2010-05-07
JP4036343B2 (ja) 2008-01-23
EP1708992A1 (de) 2006-10-11
HN2005000030A (es) 2009-04-20
ECSP066701A (es) 2006-10-31
SI1708992T1 (sl) 2007-12-31
CN1910144A (zh) 2007-02-07
AP2006003671A0 (en) 2006-06-30
PL1708992T3 (pl) 2007-12-31
MY139690A (en) 2009-10-30
CA2553293C (en) 2010-12-14
PT1708992E (pt) 2007-11-16
EA009735B1 (ru) 2008-02-28
NZ548235A (en) 2010-05-28
ES2289691T3 (es) 2008-02-01
CA2553293A1 (en) 2005-09-01
UY28724A1 (es) 2005-08-31
EP1708992B1 (de) 2007-08-08
ATE369333T1 (de) 2007-08-15
TW200530164A (en) 2005-09-16
GEP20084452B (en) 2008-08-10
TWI273099B (en) 2007-02-11
AP2378A (en) 2012-03-08
PA8621901A1 (es) 2006-03-24
DE602005001929T2 (de) 2007-12-06
KR100785580B1 (ko) 2007-12-13
CY1106894T1 (el) 2012-09-26
CN1910144B (zh) 2010-06-09
MA28303A1 (fr) 2006-11-01
IL176629A (en) 2011-04-28
PE20050765A1 (es) 2005-10-31
CO5720993A2 (es) 2007-01-31
WO2005080324A8 (en) 2006-02-23
EA200601141A1 (ru) 2007-02-27
AU2005214154B2 (en) 2008-01-24
DE602005001929D1 (de) 2007-09-20
AR047510A1 (es) 2006-01-25
OA13361A (en) 2007-04-13
NL1028086A1 (nl) 2005-07-25

Similar Documents

Publication Publication Date Title
HRP20070452T3 (hr) Sulfonamidni derivati namijenjeni liječenju bolesti
AR047509A1 (es) Derivados de sulfonamida como antagonistas de receptores adrenergicos beta2
CR10034A (es) Derivados de oxadiazol
AR044475A1 (es) Derivados de 2-amino -piridina utiles para el tratamiento de enfermedades
MXPA05011666A (es) Compuestos de pirazol-amida aril-sustituidos utiles como inhibidores de cinasa.
HRP20030448B1 (en) Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
HRP20040977B1 (hr) Derivati n-[fenil(piperidin-2-il)metil]benzamida,postupak njihovog pripravljanja i primjena istih u terapiji
CY1111310T1 (el) Ενωσεις για την αγωγη μεταβολικων διαταραχων
CO5261616A1 (es) Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
AR045255A1 (es) Derivados de 1,2 benzodiazol
HRP20070203T3 (hr) Derivati n-[fenil(alkilpiperidin-2-il)metil]benzamida, njihovo dobivanje i njihova primjena u terapiji
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
HRP20070307T3 (hr) Derivati n-[fenil(pirolidin-2-il)metil]benzamida i n-[(azepan-2-il)fenilmetil]benzamida, postupak njihovog dobivanja i njihova upotreba u terapiji
CO5690588A2 (es) Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor
CO5611152A2 (es) Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen
WO2007099162A3 (fr) Derive de resveratrol a longue chaine hydroxylee utiles comme neurotrophiques
AR044476A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
AR048322A1 (es) Compuestos para el tratamiento de afecciones inflamatorias, alergicas y respiratorias
ECSP077394A (es) Compuestos aromáticos de arilsulfonilmetil o arilsulfonamida sustituida apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
CO5690608A2 (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
WO2000032578A8 (en) Benzimidazole compounds that are vitronectin receptor antagonists
AR057464A1 (es) Procedimiento para la preparacion de derivados de sulfonamida
AR061518A1 (es) Derivados de aril y heteroaril tetrahidrobenzacepina y su uso para tratar glaucoma
BR0208823A (pt) Composto, método de tratamento de distúrbios que são remediados ou aliviados pela atividade de agonista de vasopressina em um mamìfero necessitando do mesmo, e, composição farmacêutica